ProKidney's cash runway ends near the time its Phase 3 kidney data are due
The US cell therapy company has mapped a path from trial data to a possible 2029 launch for rilparencel, but its stated funding horizon is shorter than that path.
ProKidney's commercial case for rilparencel now depends on a tight sequence. A corporate presentation dated 9 November 2026 says the company's cash is expected to last until around mid-2027, roughly when it expects the first efficacy results from its Phase 3 programme. The summary of the presentation does not say how the company intends to finance the period after that.
Rilparencel is an autologous cell therapy, made from the patient's own cells. It is being tested in the PROACT 1 trial in people with Stage 3b/4 chronic kidney disease and type 2 diabetes. ProKidney says enrolment of more than 500 patients should finish in the first quarter of 2027, with topline results on the rate of change in estimated glomerular filtration rate (eGFR) due in the second quarter.
If the data support it, the company plans to file a Biologics License Application in the first quarter of 2028, asking the US Food and Drug Administration for accelerated approval. It is aiming for a market launch in the first half of 2029. The company points to a Regenerative Medicine Advanced Therapy (RMAT) designation for the programme. The dates are ProKidney's own projections, not regulatory commitments, and depend on trial results and agency review.
The presentation as summarised gives no detail on manufacturing capacity, pricing or expected revenue, so the commercial scale of any launch cannot yet be assessed.
Why it matters
- The stated cash horizon and the expected Phase 3 data fall in the same window, making the readout a likely test of ProKidney's access to capital as well as of the therapy.
- The filing plan rests on eGFR-slope data supporting an accelerated approval request, so the quality of the PROACT 1 result will shape the regulatory strategy.
- A first-half 2029 launch target gives market-access and manufacturing planners a reference date, though it is conditional on results and FDA review.
Company's press release (SEC filing): Prokidney Corp. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
